We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

49 hedge funds and large institutions have $259M invested in Adaptimmune Therapeutics in 2016 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 6

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

4% more capital invested

Capital invested by funds: $250M → $259M (+$9.01M)

0% more funds holding

Funds holding: 49 → 49 (0)

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

Holders
49
Holders Change
–
Holders Change %
0%
% of All Funds
1.31%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
12
Increased
13
Reduced
6
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$80.8M
2
Millennium Management
Millennium Management
New York
+$4.68M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.98M
4
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$3.51M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.45M

Top Sellers

Rank Fund Capital Flow
1
EAM
EverPoint Asset Management
Connecticut
-$3.92M
2
UBS AM
UBS AM
Illinois
-$2.55M
3
Marshall Wace
Marshall Wace
United Kingdom
-$1.7M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.57M
5
GTC
Ghost Tree Capital
New York
-$1.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
EIM
26
Essex Investment Management
Massachusetts
$492K +$495K +60,575 New
CLOS
27
Compagnie Lombard Odier SCmA
Switzerland
$468K +$409K +50,000 +661%
PI
28
Putnam Investments
Massachusetts
$419K – – –
GTC
29
Ghost Tree Capital
New York
$407K -$1.31M -160,000 -76%
PC
30
Polar Capital
United Kingdom
$407K +$409K +50,000 New
AC
31
Ascend Capital
California
$406K +$409K +50,000 New
Creative Planning
32
Creative Planning
Kansas
$264K +$81.4K +9,950 +44%
VEA
33
Virtus ETF Advisers
New York
$229K +$230K +28,182 New
CAM
34
Cormorant Asset Management
Massachusetts
$203K – – –
PCM
35
Prelude Capital Management
New York
$202K +$204K +24,900 New
State of New Jersey Common Pension Fund D
36
State of New Jersey Common Pension Fund D
New Jersey
$195K – – –
FAM
37
Fred Alger Management
New York
$187K -$287K -35,150 -60%
ARTA
38
A.R.T. Advisors
New York
$175K -$3.27K -400 -2%
NSEDCP
39
NJ State Employees Deferred Compensation Plan
New Jersey
$151K – – –
D.E. Shaw & Co
40
D.E. Shaw & Co
New York
$96K +$96.8K +11,832 New
Morgan Stanley
41
Morgan Stanley
New York
$78K +$36.3K +4,443 +86%
RI
42
RTW Investments
New York
$63K +$5.2K +636 +9%
GT
43
Glenmede Trust
Pennsylvania
$25K – – –
DADC
44
D.A. Davidson & Co
Montana
$8K – – –
OAJ
45
Ogorek Anthony Joseph
New York
$8K – – –
Wells Fargo
46
Wells Fargo
California
$7K +$1.64K +200 +33%
Bank of America
47
Bank of America
North Carolina
$3K +$2.89K +353 New
VIA
48
Vident Investment Advisory
Georgia
$1.15K +$536K +65,546 +87%
EAM
49
EverPoint Asset Management
Connecticut
– -$3.92M -325,000 Closed
UBS AM
50
UBS AM
Illinois
– -$2.55M -211,555 Closed
1
2
3

ADAP Hedge Fund Activity: Q1 2016 in Review

49 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2016, worth a combined $259M — up 3.6% from $250M a quarter earlier.

Fund positioning in ADAP was balanced in Q1 2016: 12 funds opened new positions, 12 closed out, 13 added to existing stakes and 6 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $80.8M. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $3.92M sold.

  • 49 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $259M of Adaptimmune Therapeutics stock for Q1 2016, up 3.6% quarter-over-quarter.
  • 12 funds opened new Adaptimmune Therapeutics positions in Q1 2016 and 12 closed out, a net change of 0 holders.
  • The largest Adaptimmune Therapeutics buyer in Q1 2016 was NEA Management Company, an estimated $80.8M added.
  • The largest Adaptimmune Therapeutics seller in Q1 2016 was EverPoint Asset Management, an estimated $3.92M sold.

Based on aggregated 13F filings for Q1 2016.